Viral gene therapy

Converting a virus into a vector the viral life cycle can be divided into two temporally distinct phases: infection and replication. For gene therapy to be successful, an appropriate amount of a therapeutic gene must be delivered into the target tissue without substantial toxicity. Each viral vector system is characterized by an inherent set of properties that affect its suitability for specific gene therapy applications. For some disorders, long term expression from a relatively small proportion of cells would be sufficient (for example, genetic disorders), whereas other pathologies might require high, but transient, gene expression. For example, gene therapies designed to interfere with a viral infectious process or inhibit the growth of cancer cells by reconstitution of inactivated tumor suppressor genes may require gene transfer into a large fraction of the abnormal cells.

    Related Conference of Viral gene therapy

    April 03-04, 2023

    International Conference on Aging and Gerontology

    Rome, Aland Islands
    May 03-04, 2023

    16th World Congress on Stem Cell Research

    Paris, France
    May 03-04, 2023

    Global Conference on Cell and Gene Therapy

    Paris, France
    June 08-09, 2023

    10th World Congress on Epigenetics and Chromosome

    Valencia, Spain
    August 21-22, 2023

    6th Annual Conference on Stem Cell and Regenerative Medicine

    Frankfurt, Germany
    September 25-26, 2023

    19th Global Summit on Stem Cell & Regenerative Medicine

    Zurich, Switzerland
    October 19-20, 2023

    5th Annual summit on Cell Signaling and Cancer Therapy

    Montreal, Canada
    December 07-08, 2023

    17th International Conference on Genomics & Pharmacogenomics

    San Francisco, USA

    Viral gene therapy Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in